Patient characteristics
| Characteristic . | Total . | Filgrastim . | Placebo . | P Value . |
|---|---|---|---|---|
| Number | 50 | 26 | 24 | |
| Sex | .27 | |||
| Males | 27 | 12 | 15 | |
| Females | 23 | 14 | 9 | |
| Age, y | .50 | |||
| Median | 44 | 44 | 41 | |
| Range | 20-60 | 20-60 | 25-58 | |
| Diagnosis | .54 | |||
| CML | 19 | 13 | 6 | .41 |
| First chronic phase | 10 | 5 | ||
| First accelerated phase | 2 | 0 | ||
| Unknown | 1 | 1 | ||
| AML | 6 | 2 | 4 | .40 |
| CR1 | 2 | 1 | ||
| CR2 | 0 | 3 | ||
| NHL | 16 | 8 | 8 | 1.0 |
| PIF-resistant | 1 | 1 | ||
| PIF-sensitive | 2 | 3 | ||
| PIF-untreated | 1 | 0 | ||
| CR1 | 0 | 1 | ||
| CR2 | 1 | 0 | ||
| First relapse—untreated | 1 | 0 | ||
| First relapse—sensitive | 0 | 1 | ||
| Second relapse—untreated | 1 | 0 | ||
| Unknown | 1 | 2 | ||
| MDS | 3 | 1 | 2 | 1.0 |
| CR1 | 0 | 1 | ||
| Untreated | 1 | 0 | ||
| Unknown | 0 | 1 | ||
| CLL | 3 | 1 | 2 | 1.0 |
| Rai stage II | 0 | 1 | ||
| Rai stage IV | 1 | 1 | ||
| MM | 3 | 1 | 2 | 1.0 |
| CR | 0 | 1 | ||
| Unknown | 2 | 0 | ||
| HLA matching | 1.0 | |||
| 6/6 | 48 | 25 | 23 | |
| 5/6 | 2 | 1 | 1 | |
| ABO compatibility | .61 | |||
| Compatible | 16 | 14 | ||
| Minor incompatibility | 3 | 5 | ||
| Major incompatibility | 7 | 4 | ||
| Unknown | — | 1 | ||
| CMV serology (donor and/or recipient) | .13 | |||
| Negative | 6 | 10 | ||
| Positive | 20 | 12 | ||
| Unknown | 0 | 2 |
| Characteristic . | Total . | Filgrastim . | Placebo . | P Value . |
|---|---|---|---|---|
| Number | 50 | 26 | 24 | |
| Sex | .27 | |||
| Males | 27 | 12 | 15 | |
| Females | 23 | 14 | 9 | |
| Age, y | .50 | |||
| Median | 44 | 44 | 41 | |
| Range | 20-60 | 20-60 | 25-58 | |
| Diagnosis | .54 | |||
| CML | 19 | 13 | 6 | .41 |
| First chronic phase | 10 | 5 | ||
| First accelerated phase | 2 | 0 | ||
| Unknown | 1 | 1 | ||
| AML | 6 | 2 | 4 | .40 |
| CR1 | 2 | 1 | ||
| CR2 | 0 | 3 | ||
| NHL | 16 | 8 | 8 | 1.0 |
| PIF-resistant | 1 | 1 | ||
| PIF-sensitive | 2 | 3 | ||
| PIF-untreated | 1 | 0 | ||
| CR1 | 0 | 1 | ||
| CR2 | 1 | 0 | ||
| First relapse—untreated | 1 | 0 | ||
| First relapse—sensitive | 0 | 1 | ||
| Second relapse—untreated | 1 | 0 | ||
| Unknown | 1 | 2 | ||
| MDS | 3 | 1 | 2 | 1.0 |
| CR1 | 0 | 1 | ||
| Untreated | 1 | 0 | ||
| Unknown | 0 | 1 | ||
| CLL | 3 | 1 | 2 | 1.0 |
| Rai stage II | 0 | 1 | ||
| Rai stage IV | 1 | 1 | ||
| MM | 3 | 1 | 2 | 1.0 |
| CR | 0 | 1 | ||
| Unknown | 2 | 0 | ||
| HLA matching | 1.0 | |||
| 6/6 | 48 | 25 | 23 | |
| 5/6 | 2 | 1 | 1 | |
| ABO compatibility | .61 | |||
| Compatible | 16 | 14 | ||
| Minor incompatibility | 3 | 5 | ||
| Major incompatibility | 7 | 4 | ||
| Unknown | — | 1 | ||
| CMV serology (donor and/or recipient) | .13 | |||
| Negative | 6 | 10 | ||
| Positive | 20 | 12 | ||
| Unknown | 0 | 2 |
CML indicates chronic myelogenous leukemia; AML, acute myelogenous leukemia; CR, complete remission; NHL, non-Hodgkin lymphoma; PIF, primary induction failure; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; CMV, cytomegalovirus.